Otsuka Precision Health will continue advancing
Otsuka’s longstanding work in digital by delivering
first-of-its-kind, evidence-based patient experience service to
overcome common and overlooked barriers to care delivery along an
individual’s health journey.
Otsuka America, Inc. (OAI) announces Otsuka Precision Health,
Inc. (OPH), a company that will serve as a catalyst for delivering
the right interventions at the right time along patients’ and
caregivers’ unique health journeys, ranging from connected health
solutions to digital therapeutics, all powered by advanced
analytics tools like artificial intelligence. OPH will focus on the
patient experience as a core piece of improving how better outcomes
might be achieved across nephrology, mental health, and beyond.
The recent U.S. Food and Drug Administration (FDA) clearance of
Rejoyn™, the first prescription digital therapeutic authorized for
the adjunctive treatment of major depressive disorder (MDD)
symptoms, is a proof-point for the possibilities of what OPH can
bring to the market to enable a better patient experience. OPH will
serve to commercialize Rejoyn™.
“Changes are needed to realize the potential of technology in
health, and we’re ready to boldly address the barriers patients
face in receiving care by taking a fundamentally new approach,”
said Sanket Shah, president of OPH. “This Company will allow us to
build on our commitment to the digital and technology space and
continue building momentum with products such as, Rejoyn™, in a way
that traditional pharmaceutical companies have not been able to
explore.”
Combining the evidence-based rigor of pharma with a data-first
focus on a more individualized approach to supporting patients, OPH
has a unique opportunity to bring promising innovations to market
quickly. Otsuka is deepening its commitment to the meaningful role
technology can play in the lives of patients and the care teams
that surround them.
“At this time there is a great desire for alternative therapies
and treatments in the mental health space, especially given the
outpaced demand in recent years,” said Shah. “New interventions
that better connect, engage, and personalize care will be welcomed
by patients and providers.”
OPH will be exhibiting Rejoyn™ for the first time at the 2024
American Psychiatric Association (APA) Annual Meeting in New York
City from May 4 to May 8 and will participate in the meeting’s
Mental Health Innovation Zone on May 4 and May 6.
About Otsuka Precision Health
Combining the rigor of pharma with a data-first focus on patient
experience, Otsuka Precision Health, Inc. focuses on bringing to
market prescription digital therapeutics, other innovative
technologies, and provides non-promotional patient support
services. The company is committed to personalizing care, unlocking
doors to access, and uniting a fragmented experience. OPH’s current
focus areas include a variety of technological interventions that
help unearth personal health needs and address them as a true
collaborator within the broader healthcare ecosystem.
OPH is a subsidiary of Otsuka America, Inc. (Otsuka), which is a
subsidiary of Otsuka Pharmaceutical Co., Ltd. headquartered in
Tokyo, Japan.
For more information, please visit https://otsuka-oph.com/.
About Rejoyn™
Rejoyn™ (developed as CT-152), is the first prescription digital
therapeutic authorized in the U.S. for the adjunctive treatment of
major depressive disorder (MDD) symptoms. Otsuka America, Inc.
(OAI) and Click Therapeutics, Inc., signed a collaboration
agreement to develop and commercialize prescription digital
therapeutics for treatment of MDD, with the intent to address unmet
medical needs among this patient population and to improve
outcomes. Rejoyn™ is the first FDA-cleared treatment resulting from
this collaboration.
Rejoyn™ requires a prescription from a healthcare provider and
is expected to be available for download from app stores for iOS®
and Android™ operating systems in the latter half of 2024. To learn
more about Rejoyn™ and sign up for updates regarding its
availability, go to www.rejoyn.com. Healthcare providers can
visit www.rejoynhcp.com.
INDICATION and SAFETY INFORMATION for Rejoyn™
INDICATION:
Rejoyn™ is a prescription digital therapeutic for the treatment
of Major Depressive Disorder (MDD) symptoms as an adjunct to the
clinician-managed outpatient care for adult patients with MDD age
22 years and older who are on antidepressant medication. It is
intended to reduce MDD symptoms.
SAFETY INFORMATION:
Rejoyn™ is not intended to be used as a standalone therapy or a
substitute for medication. Patients should continue their current
treatment as directed.
Rejoyn™ does not monitor the patient’s symptoms or clinical
status and cannot send or receive alerts or warnings to the
prescriber.
Patients should be clearly instructed that if they believe their
depression is worsening or if they have feelings or thoughts of
harming themselves or others, to contact a healthcare professional,
dial 911, or go to the nearest emergency room immediately.
About the Otsuka and Click Therapeutics Collaboration
Otsuka America, Inc. (OAI) and Click Therapeutics, Inc., signed
a collaboration agreement in 2019 to develop and commercialize
prescription digital therapeutics for the treatment of MDD, with
the intent to address unmet medical needs among this patient
population and to improve outcomes. Rejoyn™ is the first
FDA-cleared treatment resulting from this collaboration.
About Click Therapeutics
Click Therapeutics, Inc., develops, validates, and
commercializes software as prescription medical treatments for
people with unmet medical needs. As a leading innovator of Digital
Therapeutics™, we deliver accessible, clinically proven,
FDA-regulated prescription treatments to the smartphone in your
hand. Our treatments are defined by our commitment to applying
technical and scientific rigor and patient-centric design to the
development process. This results in uniquely engaging experiences
that achieve compelling clinical outcomes for patients seeking new
treatment options. We are continuously expanding and refining our
shared platform technologies with novel cognitive, behavioral and
neuromodulatory mechanisms of action and advanced data-driven tools
such as artificial intelligence and machine learning.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506526599/en/
Otsuka Precision Health Frank Chavez Head, Strategy &
Corporate Development Otsuka Precision Health
frank.chavez@otsuka-oph.com Otsuka in Japan Jeffrey Gilbert
Leader, Pharmaceutical PR Otsuka Pharmaceutical, Co., Ltd.
gilbert.jeffrey.a@otsuka.co.jp